Similar articles

• [Comparison of various cyclophosphamide treatment regimens on the course and outcome of lupus nephritis ].

  Petrović R, Stojanović R, Novicić-Sasić D, Dimitrijević J, Pavlović S, Stojković D, Palić-Obradović D, Stevanović G, Prodanović S. Petrović R, et al. Srp Arh Celok Lek. 2002 Aug;130 Suppl 3:19-25. Srp Arh Celok Lek. 2002. PMID: 12583309 Serbian.
• Cyclophosphamide for severe lupus nephritis: where are we now?

  Mok CC. Mok CC. Arthritis Rheum. 2004 Dec;50(12):3748-50. doi: 10.1002/art.20667. Arthritis Rheum. 2004. PMID: 15593210 No abstract available.
• Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide.

  Houssiau FA, Vasconcelos C, D'Cruz D, Sebastiani GD, Garrido Ed Ede R, Danieli MG, Abramovicz D, Blockmans D, Mathieu A, Direskeneli H, Galeazzi M, Gül A, Levy Y, Petera P, Popovic R, Petrovic R, Sinico RA, Cattaneo R, Font J, Depresseux G, Cosyns JP, Cervera R. Houssiau FA, et al. Arthritis Rheum. 2002 Aug;46(8):2121-31. doi: 10.1002/art.10461. Arthritis Rheum. 2002. PMID: 12209517 Clinical Trial.
• Treatment and outcome of lupus nephritis at the turn of the millennium.

  Uppal SS. Uppal SS. J Assoc Physicians India. 1999 Sep;47(9):857-61. J Assoc Physicians India. 1999. PMID: 10778651 Review. No abstract available.
• This house believes that low-dose intravenous cyclophosphamide is superior to standard high-dose regimes for treatment of lupus nephritis.

  Gorman C, Bhatia A, Rahman A. Gorman C, et al. Rheumatology (Oxford). 2005 Mar;44(3):398-401. doi: 10.1093/rheumatology/keh440. Epub 2004 Oct 19. Rheumatology (Oxford). 2005. PMID: 15494351 Review. No abstract available.